SG11201809875VA - Compositions and methods for treating spinal muscular atrophy - Google Patents

Compositions and methods for treating spinal muscular atrophy

Info

Publication number
SG11201809875VA
SG11201809875VA SG11201809875VA SG11201809875VA SG11201809875VA SG 11201809875V A SG11201809875V A SG 11201809875VA SG 11201809875V A SG11201809875V A SG 11201809875VA SG 11201809875V A SG11201809875V A SG 11201809875VA SG 11201809875V A SG11201809875V A SG 11201809875VA
Authority
SG
Singapore
Prior art keywords
international
methods
pct
spinal muscular
treating spinal
Prior art date
Application number
SG11201809875VA
Other languages
English (en)
Inventor
Ted Yednock
Sethu Sankaranarayanan
Original Assignee
Annexon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annexon Inc filed Critical Annexon Inc
Publication of SG11201809875VA publication Critical patent/SG11201809875VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2878—Muscular dystrophy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201809875VA 2016-05-09 2017-05-09 Compositions and methods for treating spinal muscular atrophy SG11201809875VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662333348P 2016-05-09 2016-05-09
PCT/US2017/031801 WO2017196874A1 (en) 2016-05-09 2017-05-09 Compositions and methods for treating spinal muscular atrophy

Publications (1)

Publication Number Publication Date
SG11201809875VA true SG11201809875VA (en) 2018-12-28

Family

ID=60266798

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809875VA SG11201809875VA (en) 2016-05-09 2017-05-09 Compositions and methods for treating spinal muscular atrophy

Country Status (10)

Country Link
US (1) US20190161535A1 (ja)
EP (1) EP3454901A4 (ja)
JP (1) JP2019514994A (ja)
KR (1) KR20190005944A (ja)
CN (1) CN109475625A (ja)
AU (1) AU2017264690A1 (ja)
CA (1) CA3023667A1 (ja)
IL (1) IL262830A (ja)
SG (1) SG11201809875VA (ja)
WO (1) WO2017196874A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015017341A (es) 2013-07-09 2016-07-06 Anexxon Inc Anticuerpos anti-factor del complemento c1q y uso de los mismos.
SG11201803703UA (en) * 2015-11-24 2018-06-28 Annexon Inc Anti-complement factor c1q fab fragments and uses thereof
WO2019137922A1 (en) * 2018-01-09 2019-07-18 Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie Modulators of c1q, in particular of the interaction of apoe with c1q, and uses of the modulators in the therapy of neuronal diseases and inflammation
SG11202106990PA (en) * 2018-12-28 2021-07-29 Kyowa Kirin Co Ltd BISPECIFIC ANTIBODY BINDING TO TfR
KR20230049663A (ko) * 2020-07-31 2023-04-13 락티젠 세러퓨틱스 saRNA 및 mRNA 조절제들에 의한 SMA의 조합 치료
EP4337332A2 (en) 2021-07-13 2024-03-20 Mabwell Therapeutics Inc. Anti-c1s antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530454A (ja) * 2004-03-26 2007-11-01 プロミックス・ピーティーワイ・リミテッド 補体Ｃ５ａ受容体モジュレーターを使用する神経疾患の治療
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
WO2007070375A2 (en) * 2005-12-09 2007-06-21 The Board Of Trustees Of The Leland Stanford Junior University Modulation of synaptic maintenance
EA034333B1 (ru) * 2010-11-30 2020-01-29 Дженентек, Инк. Варианты антитела для переноса соединения через гематоэнцефалический барьер
EP2996722A4 (en) * 2013-05-15 2017-01-11 Annexon, Inc. Methods of treatment for guillain-barre syndrome
MX2015017341A (es) * 2013-07-09 2016-07-06 Anexxon Inc Anticuerpos anti-factor del complemento c1q y uso de los mismos.
JP6951246B2 (ja) * 2014-11-05 2021-10-20 アネクソン，インコーポレーテッド ヒト化抗補体因子Ｃ１ｑ抗体及びその使用

Also Published As

Publication number Publication date
US20190161535A1 (en) 2019-05-30
EP3454901A1 (en) 2019-03-20
WO2017196874A1 (en) 2017-11-16
CN109475625A (zh) 2019-03-15
CA3023667A1 (en) 2017-11-16
EP3454901A4 (en) 2020-07-29
JP2019514994A (ja) 2019-06-06
IL262830A (en) 2018-12-31
AU2017264690A1 (en) 2018-11-29
KR20190005944A (ko) 2019-01-16

Similar Documents

Publication Publication Date Title
SG11201909949XA (en) Targeted immunotolerance
SG11201809875VA (en) Compositions and methods for treating spinal muscular atrophy
SG11201811432WA (en) Rna for cancer therapy
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201803906PA (en) Control of cellular redox levels
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201909011PA (en) Niraparib compositions
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201900123TA (en) Compositions and methods for treating frontotemporal dementia
SG11201808306PA (en) Treatment of cancer with tg02
SG11201805001UA (en) Method of treating influenza a
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201900405XA (en) Compounds, compositions and methods for treating or preventing a sympton associated with gout or hyperuricemia
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201902531QA (en) Liquid pharmaceutical composition
SG11201811686UA (en) 18f-labeled triazole containing psma inhibitors
SG11201809531SA (en) BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201805900YA (en) Inhibition of allergic reaction using an il-33 inhibitor
SG11201809223PA (en) Erbb inhibitors and uses thereof
SG11201908393YA (en) Modulators of pcsk9 expression